Highlights Crescita Therapeutics Inc.

Equities

CTX

CA2258471028

Market Closed - Toronto S.E. Other stock markets 15:53:05 21/05/2024 BST			5-day change	1st Jan Change
0.47 ^CAD	-1.05%		+9.30%	-4.08%

05-08	Crescita Therapeutics Q1 Loss Widens, Revenue Rises	MT
05-08	Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crescita Therapeutics Q1 Loss Widens, Revenue Rises	05-08	MT
Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million	05-08	MT
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	03-13	MT
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	03-13	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01	03-13	MT
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
North American Morning Briefing : Stock Futures -2-	03-13	DJ
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	11-08	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid	29/08/23	MT
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid	29/08/23	MT
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	29/08/23	CI
Crescita Therapeutics Inc. authorizes a Buyback Plan.	28/08/23	CI
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter	09/08/23	MT
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland	01/06/23	CI
Crescita Therapeutics Q1 Revenue was $4.6 Million; Cites Cash Balance of $10.3M	11/05/23	MT
Crescita Therapeutics Brief: Q1 Revenue was $4.602 Million; Cites Cash Balance of $10.3M	11/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Crescita Therapeutics Inc.

Equities

CTX

CA2258471028

Highlights

Filters